Latest / Decera Clinical Education Oncology Podcast
Takeaways From a Large Educational Program on Available and Emerging Treatment Options for HER2-Positive mBC
In this episode, listen to Laura M. Spring, MD; and Shipra Gandhi, MD, MS, share their takeaways from a large educational program on available and emerging first-line treatment options for patients with HER2-positive mBC:
Emerging new data from the phase IIII DESTINY-Breast09 trial of first-line treatment with trastuzumab deruxtecan ± pertuzumab vs THP for advanced HER2-positive breast cancer
Interactive decision support tool with recommendations from 5 experts for the treatment of HER2-positive breast cancer
Outcomes data from a live webinar on applying the latest data for first-line…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.